http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 24 Jul 2026 17:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSMED+Inc++++++++++++++++For%3A+Jul+23++Filed+by%3A+Lewis+William/26814237.html si-local-file:///var/storage/secattach/20260724/26814237.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSMED+Inc++++++++++++++++For%3A+Jul+23++Filed+by%3A+Lewis+William/26814237.html Fri, 24 Jul 2026 17:02:00 -0400 INSM O.00646555 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSMED+Inc++++++++++++++++For%3A+Jul+23++Filed+by%3A+Lewis+William/26814237.html si-local-file:///var/storage/secattach/20260724/26814237.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INSMED+Inc++++++++++++++++For%3A+Jul+23++Filed+by%3A+Lewis+William/26814237.html Fri, 24 Jul 2026 17:02:00 -0400 INSM O.00646555 http://www.streetinsider.com/SEC+Filings/Form++144++++++++INSMED+Inc+++++++++++++++++++++++++++++Filed+by%3A+Lewis+William/26808688.html si-local-file:///var/storage/secattach/20260723/26808688.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++INSMED+Inc+++++++++++++++++++++++++++++Filed+by%3A+Lewis+William/26808688.html Thu, 23 Jul 2026 16:39:00 -0400 INSM O.00646555 http://www.streetinsider.com/SEC+Filings/Form++144++++++++INSMED+Inc+++++++++++++++++++++++++++++Filed+by%3A+Lewis+William/26808688.html si-local-file:///var/storage/secattach/20260723/26808688.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++INSMED+Inc+++++++++++++++++++++++++++++Filed+by%3A+Lewis+William/26808688.html Thu, 23 Jul 2026 16:39:00 -0400 INSM O.00646555 http://www.streetinsider.com/Press+Releases/Insmed+to+Host+Second-Quarter+2026+Financial+Results+Conference+Call+on+Thursday%2C+August+6%2C+2026/26804273.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.briter" idsrc="xmltag.org" >BRIDGEWATER, N.J.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INSM" idsrc="xmltag.org" >Insmed Incorporated</span> (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2026 financial results on Thursday, August 6, 2026.</p><p><span value="NASDAQ-NMS:INSM" idsrc="xmltag.org" >Insmed</span> management will host a conference call for investors beginning at 8:00 a.m. ET on <chron>Thursday, August 6, 2026</chron>, to discuss financial results and provide a business update.</p><p>Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (<location http://www.streetinsider.com/Press+Releases/Insmed+to+Host+Second-Quarter+2026+Financial+Results+Conference+Call+on+Thursday%2C+August+6%2C+2026/26804273.html Thu, 23 Jul 2026 07:00:00 -0400 INSM O.00646555 http://www.streetinsider.com/Press+Releases/Insmed+to+Host+Second-Quarter+2026+Financial+Results+Conference+Call+on+Thursday%2C+August+6%2C+2026/26804273.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.briter" idsrc="xmltag.org" >BRIDGEWATER, N.J.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INSM" idsrc="xmltag.org" >Insmed Incorporated</span> (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2026 financial results on Thursday, August 6, 2026.</p><p><span value="NASDAQ-NMS:INSM" idsrc="xmltag.org" >Insmed</span> management will host a conference call for investors beginning at 8:00 a.m. ET on <chron>Thursday, August 6, 2026</chron>, to discuss financial results and provide a business update.</p><p>Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (<location http://www.streetinsider.com/Press+Releases/Insmed+to+Host+Second-Quarter+2026+Financial+Results+Conference+Call+on+Thursday%2C+August+6%2C+2026/26804273.html Thu, 23 Jul 2026 07:00:00 -0400 INSM O.00646555 http://www.streetinsider.com/PRNewswire/Insmed+to+Host+Second-Quarter+2026+Financial+Results+Conference+Call+on+Thursday%2C+August+6%2C+2026/26804273.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.briter" idsrc="xmltag.org" >BRIDGEWATER, N.J.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INSM" idsrc="xmltag.org" >Insmed Incorporated</span> (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2026 financial results on Thursday, August 6, 2026.</p><p><span value="NASDAQ-NMS:INSM" idsrc="xmltag.org" >Insmed</span> management will host a conference call for investors beginning at 8:00 a.m. ET on <chron>Thursday, August 6, 2026</chron>, to discuss financial results and provide a business update.</p><p>Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (<location http://www.streetinsider.com/PRNewswire/Insmed+to+Host+Second-Quarter+2026+Financial+Results+Conference+Call+on+Thursday%2C+August+6%2C+2026/26804273.html Thu, 23 Jul 2026 07:00:00 -0400 INSM O.00646555 http://www.streetinsider.com/PRNewswire/Insmed+to+Host+Second-Quarter+2026+Financial+Results+Conference+Call+on+Thursday%2C+August+6%2C+2026/26804273.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.briter" idsrc="xmltag.org" >BRIDGEWATER, N.J.</location></span>, <span class="legendSpanClass"><chron>July 23, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INSM" idsrc="xmltag.org" >Insmed Incorporated</span> (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2026 financial results on Thursday, August 6, 2026.</p><p><span value="NASDAQ-NMS:INSM" idsrc="xmltag.org" >Insmed</span> management will host a conference call for investors beginning at 8:00 a.m. ET on <chron>Thursday, August 6, 2026</chron>, to discuss financial results and provide a business update.</p><p>Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (<location http://www.streetinsider.com/PRNewswire/Insmed+to+Host+Second-Quarter+2026+Financial+Results+Conference+Call+on+Thursday%2C+August+6%2C+2026/26804273.html Thu, 23 Jul 2026 07:00:00 -0400 INSM O.00646555 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++INSMED+Inc+++++++++++++++++++++++++++++Filed+by%3A+JPMORGAN+CHASE+%26amp%3B+CO/26800814.html si-local-file:///var/storage/secattach/20260722/26800814.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++INSMED+Inc+++++++++++++++++++++++++++++Filed+by%3A+JPMORGAN+CHASE+%26amp%3B+CO/26800814.html Wed, 22 Jul 2026 13:39:00 -0400 INSM O.00646555 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++INSMED+Inc+++++++++++++++++++++++++++++Filed+by%3A+JPMORGAN+CHASE+%26amp%3B+CO/26800814.html si-local-file:///var/storage/secattach/20260722/26800814.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++INSMED+Inc+++++++++++++++++++++++++++++Filed+by%3A+JPMORGAN+CHASE+%26amp%3B+CO/26800814.html Wed, 22 Jul 2026 13:39:00 -0400 INSM O.00646555 http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html <p>Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.</p><p>For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.</p><p>United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales http://www.streetinsider.com/General+News/Raymond+James+sees+potential+for+beats+across+biopharma+coverage/26791691.html Tue, 21 Jul 2026 06:12:05 -0400 INSM IONS JAZZ MIST PTCT TNXP TXNP UTHR http://www.streetinsider.com/New+Coverage/BMO+Capital+Starts+Insmed+%28INSM%29+at+Outperform/26790126.html (Updated - July 20, 2026 5:01 PM EDT) <p>BMO Capital analyst Connor Mackay initiates coverage on Insmed (NASDAQ: INSM) with a Outperform rating and a price target of $192.00.</p><p>The analyst comments "We initiate coverage of Insmed Inc. with an Outperform rating and a $192 target. Our positive view is based on: 1) Brinsupri’s rapid launch in NCFB, with the potential to become a cornerstone respiratory franchise with peak sales of $9.2B; 2) Arikayce’s durable and growing MAC-LD revenue base, with the recent positive ENCORE data creating potential for expansion into a meaningfully larger front-line population; 3) TPIP’s broad Phase 3 program http://www.streetinsider.com/New+Coverage/BMO+Capital+Starts+Insmed+%28INSM%29+at+Outperform/26790126.html Mon, 20 Jul 2026 17:01:31 -0400 INSM http://www.streetinsider.com/Analyst+Comments/BMO+Capital+Starts+Insmed+%28INSM%29+at+Outperform/26790126.html (Updated - July 20, 2026 5:01 PM EDT) <p>BMO Capital analyst Connor Mackay initiates coverage on Insmed (NASDAQ: INSM) with a Outperform rating and a price target of $192.00.</p><p>The analyst comments "We initiate coverage of Insmed Inc. with an Outperform rating and a $192 target. Our positive view is based on: 1) Brinsupri’s rapid launch in NCFB, with the potential to become a cornerstone respiratory franchise with peak sales of $9.2B; 2) Arikayce’s durable and growing MAC-LD revenue base, with the recent positive ENCORE data creating potential for expansion into a meaningfully larger front-line population; 3) TPIP’s broad Phase 3 program http://www.streetinsider.com/Analyst+Comments/BMO+Capital+Starts+Insmed+%28INSM%29+at+Outperform/26790126.html Mon, 20 Jul 2026 17:01:31 -0400 INSM http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Insmed+%28INSM%29/26786696.html <p>H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $220.00 price target on Insmed (NASDAQ: INSM).</p><p>The analyst commented: "Insmed’s 12-month OLE update for TPIP was positive and showed that the strong Phase 2b efficacy signal did not fade, that patients crossing over from placebo responded similarly to patients on therapy and that chronic treatment did not uncover a hidden tolerability ceiling. In our view, the data meaningfully narrows the bear case and makes it harder to dismiss TPIP’s Phase 2 data as just aggressive statistical analysis. That said, this is de-risking, but not thesis changing since it is only http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Insmed+%28INSM%29/26786696.html Mon, 20 Jul 2026 06:44:41 -0400 INSM http://www.streetinsider.com/Analyst+Comments/Insmed+%28INSM%29+Reiterated+at+Buy+by+Stifel+After+TPIP+P2b+Trial+Data/26781876.html <p>Stifel analyst Stephen Willey reiterated a Buy rating and $200.00 price target on Insmed (NASDAQ: INSM).</p><p>The analyst commented, "We believe TPIP data from the 12-month open-label extension (OLE) portion of the P2b trial reinforce the best-inclass TPIP-mediated clinical benefit observed in the placebo-controlled randomized portion of the trial and suggest a continued depth/durability of clinical benefit (across a spectrum of endpoints) which serves to de-risk the registrational P3 development effort. While acknowledging OLE data and the inherent variability associated with disease-specific endpoints can be challenging to adjudicate in the absence of a placebo control, we believe the magnitude and consistency http://www.streetinsider.com/Analyst+Comments/Insmed+%28INSM%29+Reiterated+at+Buy+by+Stifel+After+TPIP+P2b+Trial+Data/26781876.html Fri, 17 Jul 2026 07:20:53 -0400 INSM http://www.streetinsider.com/Corporate+News/Insmed+reports+12-month+OLE+data+for+TPIP+in+PAH+patients/26776518.html <p>Insmed Incorporated (Nasdaq: INSM) released 12-month data from an ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH), according to a company statement issued July 16, 2026.</p><p>The 24-month OLE study enrolled 91 patients across 45 global sites. At month 12, patients in the TPIP Continued group (N=60) showed a mean improvement in six-minute walk distance of +55.7 meters from baseline, while the Placebo Crossed group (N=31) showed +54.1 meters. NT-proBNP concentration was reduced by approximately 60% in both groups. WHO Functional Class I or II was achieved in 78.3% of the http://www.streetinsider.com/Corporate+News/Insmed+reports+12-month+OLE+data+for+TPIP+in+PAH+patients/26776518.html Thu, 16 Jul 2026 07:02:08 -0400 INSM http://www.streetinsider.com/FDA/Insmed+reports+12-month+OLE+data+for+TPIP+in+PAH+patients/26776518.html <p>Insmed Incorporated (Nasdaq: INSM) released 12-month data from an ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH), according to a company statement issued July 16, 2026.</p><p>The 24-month OLE study enrolled 91 patients across 45 global sites. At month 12, patients in the TPIP Continued group (N=60) showed a mean improvement in six-minute walk distance of +55.7 meters from baseline, while the Placebo Crossed group (N=31) showed +54.1 meters. NT-proBNP concentration was reduced by approximately 60% in both groups. WHO Functional Class I or II was achieved in 78.3% of the http://www.streetinsider.com/FDA/Insmed+reports+12-month+OLE+data+for+TPIP+in+PAH+patients/26776518.html Thu, 16 Jul 2026 07:02:08 -0400 INSM http://www.streetinsider.com/Hot+Corp.+News/Insmed+reports+12-month+OLE+data+for+TPIP+in+PAH+patients/26776518.html <p>Insmed Incorporated (Nasdaq: INSM) released 12-month data from an ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH), according to a company statement issued July 16, 2026.</p><p>The 24-month OLE study enrolled 91 patients across 45 global sites. At month 12, patients in the TPIP Continued group (N=60) showed a mean improvement in six-minute walk distance of +55.7 meters from baseline, while the Placebo Crossed group (N=31) showed +54.1 meters. NT-proBNP concentration was reduced by approximately 60% in both groups. WHO Functional Class I or II was achieved in 78.3% of the http://www.streetinsider.com/Hot+Corp.+News/Insmed+reports+12-month+OLE+data+for+TPIP+in+PAH+patients/26776518.html Thu, 16 Jul 2026 07:02:08 -0400 INSM